A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors

Cancer Res (2016) 76 (20): 5911–5913.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase

Elena V. Koroleva
Yuri V. Kornoushenko
Anna D. Karpenko
Ivan P. Bosko
Julia V. Siniutsich
Zhanna V. Ignatovich
Alexander M. Andrianov

Journal of Biomolecular Structure and Dynamics 1.

Rational Design of Potential Bcr-Abl Tyrosine Kinase Inhibitors by the Methods of Molecular Modeling

A.M. Anrdrianov
Yu.V. Kornoushenko
A.D. Karpenko
I.P. Bosko
Zh.V. Ignatovich
E.V. Koroleva

Mathematical Biology and Bioinformatics (2020) 15 (2): 396.

Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery

Shaoyong Lu
Yuran Qiu
Duan Ni
Xinheng He
Jun Pu
Jian Zhang

Drug Discovery Today (2020) 25 (1): 177.

A comprehensive review of protein kinase inhibitors for cancer therapy

Radhamani Kannaiyan
Daruka Mahadevan

Expert Review of Anticancer Therapy (2018) 18 (12): 1249.

ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation

Rajesh Sonti
Ines Hertel-Hering
Allan Joaquim Lamontanara
Oliver Hantschel
Stephan Grzesiek

Journal of the American Chemical Society (2018) 140 (5): 1863.